GLAXF - CureVac: Remains A Hold Based On Bird Flu Vaccine And Oncology Advancements

2024-05-23 16:47:14 ET

Summary

• CureVac N.V. is developing an avian influenza [H5N1] vaccine with GSK plc; A phase 1 study is already underway to evaluate this vaccine.
• It is working on a seasonal influenza vaccine, but further optimization is needed to target influenza B; Dose-optimization is underway for a phase 2 study.
• CureVac has a promising mRNA cancer vaccine candidate for surgically resected glioblastoma, with data expected in the second half of 2024.
• A strategic co-development and licensing agreement was made with The University of Texas MD Anderson Cancer Center; potential to advance off-the-shelf mRNA cancer vaccines for hematological and solid tumor indications.

CureVac N.V. ( CVAC ) is in the process of developing an avian influenza [H5N1] vaccine with its partner GSK plc ( GSK ) aka GlaxoSmithKline. The significance of this is that there have been a few cases of avian flu noted in Australia and the United States. It is too early to tell right now, but if there is an eventual outbreak, then this company could possibly be in a position to help out with a working vaccine....

For further details see: